Targeting Low Back Pain With Sustained-Release

Micro-Suspension Platform Technology

Welcome to SpineThera

Our goal is to develop proprietary drugs that offer patients and physicians new treatment options that reduce risk, improve outcomes, and manage overall treatment costs in therapeutic areas with few or no approved drugs.
background vector
Brain Image

About Us

SpineThera is a clinical stage pharmaceutical company working to improve the lives of patients by creating injectable drugs utilizing its micro-suspension platform technology. SpineThera’s micro-suspension provides months long sustained-release of the active pharmaceutical ingredient with superior injectability at ultra-high concentrations.
The company’s lead investigational drug product, SX600, is a novel formulation of dexamethasone being developed for sciatica. SX600 is currently being investigated in a Phase 2 clinical trial.

Targeting applications requiring superior injectability (high concentration via small needle or catheter) and sustained-release that are uniquely addressed by

SpineThera’s micro-suspension platform technology.

Service Image
Enables targeting of small / challenging anatomical features with sustained release injectable formulation
Service Image
Delivers 50X higher drug concentrations through small needles or catheters
Service Image
Minimizes systemic exposure